Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BiondVax Pharmaceuticals Ltd.    BVXV

BIONDVAX PHARMACEUTICALS LTD.

(BVXV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
2.91(c) 3.29(c) 3.12(c) 3.19(c) 3.23(c) Last
370 289 1 850 500 930 183 575 305 504 346 Volume
+4.68% +13.06% -5.17% +2.24% +1.25% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -26,6 M - -
Net Debt 2020 - - -
P/E ratio 2020 -53,8x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -26,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -53,8x
Yield 2021 -
Capitalization 37,2 M 37,2 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees 25
Free-Float 58,7%
More Financials
Company
BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials... 
More about the company
All news about BIONDVAX PHARMACEUTICALS LTD.
10/26BIONDVAX PHARMACEUTICALS : Announces Topline Results from Phase 3 Clinical Trial..
AQ
10/02BIONDVAX PHARMACEUTICALS : Announces At-The-Market (ATM) Equity Offering Program
AQ
08/17BIONDVAX PHARMACEUTICALS : Corporate Presentation – August 2020
PU
07/01BIONDVAX PHARMACEUTICALS : Last of 12,400 Participants Completes Final Visit in ..
PU
06/15BIONDVAX PHARMACEUTICALS : Announces Fourth Quarter and Full Year 2019 Financial..
AQ
05/20BIONDVAX PHARMACEUTICALS : Announces Receipt of $4.2 million through Exercise of..
PU
03/24BIONDVAX PHARMACEUTICALS : New Directors Elected to BiondVax's Board of Director..
PU
03/19BIONDVAX PHARMACEUTICALS : CEO Comments on Impact of COVID-19 Pandemic on the Co..
PU
03/09BIONDVAX PHARMACEUTICALS : Corporate Presentation – March 2020
PU
02/05BIONDVAX PHARMACEUTICALS : Preliminary Data from NIH/NIAID-sponsored Phase 2 Cli..
PU
01/16BIONDVAX PHARMACEUTICALS : Announces Warrant Agreement Amendment to Permit Holde..
PU
More news
News in other languages on BIONDVAX PHARMACEUTICALS LTD.

- No features available -

More news
Chart BIONDVAX PHARMACEUTICALS LTD.
Duration : Period :
BiondVax Pharmaceuticals Ltd. Technical Analysis Chart | BVXV | US09073Q1058 | MarketScreener
Technical analysis trends BIONDVAX PHARMACEUTICALS LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price 81,00 $
Last Close Price 3,23 $
Spread / Highest target 2 408%
Spread / Average Target 2 408%
Spread / Lowest Target 2 408%
EPS Revisions
Managers
NameTitle
Ronald Babecoff President, Chief Executive Officer & Director
Mark S. Germain Chairman
Shimon Hassin Chief Operating Officer
Tamar Ben-Yedidia Chief Scientific Officer
Avner Rotman Director
Sector and Competitors
1st jan.Capitalization (M$)
BIONDVAX PHARMACEUTICALS LTD.-65.23%37
LONZA GROUP AG56.17%44 950
MODERNA, INC.458.18%39 001
CELLTRION, INC.82.32%36 284
IQVIA HOLDINGS INC.9.94%32 977
SEAGEN INC.44.80%29 684